Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 25.9%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 58,200 shares, a decline of 25.9% from the February 13th total of 78,500 shares. Based on an average trading volume of 22,900 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.5% of the company’s stock are sold short.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP traded down $0.00 during midday trading on Friday, reaching $0.81. 6,549 shares of the company’s stock were exchanged, compared to its average volume of 45,592. Indaptus Therapeutics has a 52-week low of $0.70 and a 52-week high of $3.10. The stock has a market capitalization of $11.37 million, a PE ratio of -0.47 and a beta of 1.60. The business’s fifty day moving average price is $0.86 and its two-hundred day moving average price is $1.08.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Thursday, March 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Analysts predict that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.